Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in High-Risk Older Adults in Japan
Molnupiravir is a cost-effective treatment option for the treatment of older adult outpatients (age ≥ 65 years) with symptomatic COVID-19 in Japan, relative to best supportive care.
Authors
- Atsushi Tajima (ORCID: https://orcid.org/0000-0001-9193-9934)
- Hardik Goswami
- Amy Puenpatom
- Taizo Matsuki (ORCID: https://orcid.org/0000-0002-0591-4261)
Institutions
- Gwynedd Mercy University (US)
- MSD K.K. (Japan) (JP)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1007/s41669-025-00578-y
- Citations
- 3
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- article
- Field-Weighted Citation Impact
- 4.17
Funders
- Merck